无创指标动态变化对代谢相关脂肪性肝病临床结局的评估效能

·综述·

打开文本图片集

Abstract：Histopathologicalexamnatioiscuentlyhegoldstandardforthediagnosisofmetabolicaoiatedfattliveriseae （MAFD）；however，duetoitsinvasivenes，highrisks，andlowfeasibility，applicationofnoninvasiveindicators inthestaging andclassificationofMFLDhasbecomearesearchhotspot.Thisarticlesystematicallreviews theeffcacyofdynamicchange in variousoninvasivemarkersinreflectinghistologicalchangesandclinicaloutcomeeventsinMAFLDpatients，inordertoprovide theoretical support for dynamic monitoring and individualized management of the disease.

KeyWords：Non-alcoholic Fatty Liver Disease；Biomarkers；Diagnostic Imaging；Models，Statistical

Research funding： Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support （ZLRK202301）

代谢相关脂肪性肝病（metabolicassociated fattyliverdisease，MAFLD），既往称为非酒精性脂肪性肝病（non-alcoholicfattyliverdisease，NAFLD），是一类与遗传易感性、营养过剩和代谢紊乱等因素相关的慢性进展性肝病[1]。（剩余14340字）